These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 4052520)

  • 41. Psychoimmunoendocrine aspects of panic disorder.
    Brambilla F; Bellodi L; Perna G; Battaglia M; Sciuto G; Diaferia G; Petraglia F; Panerai A; Sacerdote P
    Neuropsychobiology; 1992; 26(1-2):12-22. PubMed ID: 1335559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic dilemmas in the management of hypothalamic-pituitary-adrenal disorders.
    Biller B; Klibanski A; Koenig J; Martin JB
    Ann N Y Acad Sci; 1987; 512():338-50. PubMed ID: 3442374
    [No Abstract]   [Full Text] [Related]  

  • 43. HPA axis disturbance and treatment outcome in panic disorder.
    Coryell W; Noyes R
    Biol Psychiatry; 1988 Nov; 24(7):762-6. PubMed ID: 3067754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathophysiology of HPA axis abnormalities in patients with major depression: an update.
    Kathol RG; Jaeckle RS; Lopez JF; Meller WH
    Am J Psychiatry; 1989 Mar; 146(3):311-7. PubMed ID: 2645793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severity of depression and hypothalamic-pituitary-adrenal axis dysregulation: identification of contributing factors.
    Meador-Woodruff JH; Greden JF; Grunhaus L; Haskett RF
    Acta Psychiatr Scand; 1990 Apr; 81(4):364-71. PubMed ID: 2343764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative dexamethasone suppression test measurements in bulimia, depression and normal controls.
    Musisi S; Garfinkel P
    Can J Psychiatry; 1985 Apr; 30(3):190-4. PubMed ID: 3857956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Dexamethasone suppression test repeated after a suicide attempt].
    Wilmotte J; Van Wettere JP; Depauw Y; Charles G
    Acta Psychiatr Belg; 1986; 86(3):242-8. PubMed ID: 3751647
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder.
    Erhardt A; Ising M; Unschuld PG; Kern N; Lucae S; Pütz B; Uhr M; Binder EB; Holsboer F; Keck ME
    Neuropsychopharmacology; 2006 Nov; 31(11):2515-22. PubMed ID: 16841071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroendocrine disturbances and the diagnosis and aetiology of endogenous depression.
    Carroll BJ; Greden JF; Feinberg M
    Lancet; 1980 Feb; 1(8163):321-2. PubMed ID: 6101783
    [No Abstract]   [Full Text] [Related]  

  • 50. Dexamethasone suppression test in patients with panic disorder and secondary depression.
    Bueno JA; Sabanes F; Gascon J; Gasto C; Salamero M
    Arch Gen Psychiatry; 1984 Jul; 41(7):723-4. PubMed ID: 6732433
    [No Abstract]   [Full Text] [Related]  

  • 51. The metyrapone test in schizophrenic patients and healthy subjects.
    Morphy MA; Fava GA; Carson SW; Perini GI; Molnar G; Jusko WJ
    Neuropsychobiology; 1985; 14(1):35-8. PubMed ID: 4069347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salivary cortisol levels and the 2-year course of depressive and anxiety disorders.
    Vreeburg SA; Hoogendijk WJ; DeRijk RH; van Dyck R; Smit JH; Zitman FG; Penninx BW
    Psychoneuroendocrinology; 2013 Sep; 38(9):1494-502. PubMed ID: 23313277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversal of abnormal dexamethasone suppression test in alcoholics abstinent for four weeks.
    Del Porto JA; Monteiro MG; Laranjeira RR; Jorge MR; Masur J
    Biol Psychiatry; 1985 Nov; 20(11):1156-60. PubMed ID: 4052517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypothalamic-pituitary-adrenocortical activity in panic disorder: relationship to plasma catecholamine metabolites.
    Gurguis GN; Mefford IN; Uhde TW
    Biol Psychiatry; 1991 Sep; 30(5):502-6. PubMed ID: 1657223
    [No Abstract]   [Full Text] [Related]  

  • 55. The dexamethasone suppression test in depressed retarded adults: preliminary findings.
    Beckwith BE; Parker L; Pawlarczyk D; Couk DI; Schumacher KS; Yearwood K
    Biol Psychiatry; 1985 Aug; 20(8):825-31. PubMed ID: 4027299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid regulation of hypothalamic-pituitary-adrenal function in depression.
    Zis AP; Haskett RF; Albala AA; Carroll BJ; Lohr NE
    Arch Gen Psychiatry; 1985 Apr; 42(4):383-6. PubMed ID: 3977556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The dexamethasone suppression test in prepubertal depressed children.
    Weller EB; Weller RA; Fristad MA; Preskorn SH; Teare M
    J Clin Psychiatry; 1985 Dec; 46(12):511-3. PubMed ID: 4066616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression.
    Holsboer F; von Bardeleben U; Wiedemann K; Müller OA; Stalla GK
    Biol Psychiatry; 1987 Feb; 22(2):228-34. PubMed ID: 3028512
    [No Abstract]   [Full Text] [Related]  

  • 59. Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test.
    Roy A; Jimerson DC; Pickar D
    Am J Psychiatry; 1986 Jul; 143(7):846-51. PubMed ID: 3717423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression test.
    Deuschle M; Schweiger U; Gotthardt U; Weber B; Körner A; Schmider J; Standhardt H; Lammers CH; Krumm B; Heuser I
    Biol Psychiatry; 1998 May; 43(10):762-6. PubMed ID: 9606531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.